Alzheimer's Drugs Market is expected to reach US$ 22.01 billion by 2030
Cholinesterase Inhibitors, by Drug Class, to Dominate Alzheimer’s Drugs Market During 2022–2030
According to our new research study on "Alzheimer’s Drugs Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market is expected to grow from US$ 6.21 billion in 2022 to US$ 22.01 billion by 2030; it is estimated to record a CAGR of 17.1% during 2022–2030. The high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for addressing the condition are driving the Alzheimer’s drugs market growth. However, the side effects of drugs and the stringent regulatory environment hinder the market progress.
Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease.
Alzheimer’s Drugs Market, by Geography, 2022 (%)
To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00015800
Source: The Insight Partners Analysis
The rapid progression of Alzheimer’s disease (AD) poses a serious threat to the global healthcare system. Additionally, the high failure rate of current therapies exacerbates the problem. It is predicted that the prevalence of this disorder will increase by four times by 2050, which will put tremendous economic pressure on the medical sector worldwide. Therefore, there is an urgent need to replace traditional approaches and adopt new methods of disease prevention, treatment, and diagnosis. Precision medicine is a personalized approach to disease management that considers genetic variability, biomarker profiles, environmental influences, lifestyle factors, and the stage of the disease to develop patient-specific therapeutic interventions.
Many studies are being carried out to understand the complex nature of the disease, which has led to the development of biomarker-guided treatment as a precision medicine approach. For instance, in an article published by medRxiv in 2021, a pilot scale clinical trial was carried out to evaluate a precision medicine strategy, which involves identifying and treating the potential causes of cognitive decline in Alzheimer's disease and mild cognitive impairment (MCI). The study concluded that a precision medicine approach for cognitive decline in Alzheimer's disease and MCI would be an effective strategy, especially when continued over time.
Thus, the rising focus on personalized treatments and precision medicines for AD is expected to bring new Alzheimer’s drugs market trends in the coming years.
The Alzheimer’s drugs market analysis is carried out by identifying and evaluating key players in the market across different regions. Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited are among the prominent players profiled in the Alzheimer’s drugs market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem.
The Alzheimer’s drugs market forecast can help stakeholders plan their growth strategies. In January 2024, Eisai Co., Ltd. and Biogen Inc. announced that the distribution of their collaborative development, LEQEMBI, has been approved in China. It is a humanized, anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody developed for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia.
Similarly, in May 2023, Otsuka Pharmaceutical, Co. Ltd. and Lundbeck LLC announced that their collaborative development, supplemental New Drug Application (sNDA) of REXULTI containing brexpiprazole, received the US Food and Drug Administration (FDA) approval for the treatment of neuropsychiatric symptom in Alzheimer’s dementia.
In terms of revenue, North America dominated the Alzheimer’s drugs market share. In 2022, North America held the largest share of the global market owing to the extensive research and development activities by pharmaceutical companies, and the prevalence of AD and associated dementia in the aging population. According to the Alzheimer's Association, in 2023, over 6 million people in America were diagnosed with AD, and ~1 in 9 individuals aged 65 years or above—representing 10.7% of the American population—were affected by Alzheimer's. Additionally, according to statistics provided by the Centers for Disease Control and Prevention (CDC) in October 2020, AD is the sixth leading cause of death among US adults. Furthermore, the increasing spending on healthcare services across the US boosts the demand for AD treatment drugs, augmenting the Alzheimer’s drugs market growth in the region.
The Alzheimer’s drugs market is segmented into drug class and distribution channel.
Based on drug class, the market is subsegmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment accounted for the largest Alzheimer’s drugs market share in 2022. The pipeline drugs segment is estimated to register the highest CAGR during 2022–2030. Based on drug class, the cholinesterase inhibitors segment is further segmented into Donepezil, Galantamine, and Rivastigmine. Cholinesterase inhibitors are prescribed by specialists such as psychiatrists or neurologists for early- to mid-stage AD. These drugs boost the levels of acetylcholine in the brain, a neurotransmitter that helps nerve cells communicate with each other.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment held the largest market share. The Online pharmacies segment is anticipated to register the highest CAGR during 2022–2030.
The scope of the Alzheimer’s drugs market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Contact Person: Content Team
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
